Scientists have discovered that the peptide hormone adrenomedullin plays a pivotal role in obesity-related type 2 diabetes, ...
Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.
News Medical on MSN1d
Adrenomedullin hormone contributes to insulin resistance in obesity-associated type 2 diabetesThe hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study.
Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...
Verywell Health on MSN1d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer TypeThe FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...
The hormone triggers insulin resistance in blood vessel endothelium in obesityA large proportion of the approximately six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback